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Positively framed risk information in patient information leaflets reduces side effect 
reporting: A double-blind randomised controlled trial. 
Abstract 
Background: Many medication side effects are the result of a psychologically mediated 
“nocebo effect”, triggered by negative expectations.  
Purpose: This study investigated if changing how side effect information is framed in patient 
information leaflets (PILs) reduces symptom reporting. 
Methods: 203 healthy volunteers aged 18 or over were recruited from Dec 1 2015 to Dec 5 
2016 into a double-blind randomised controlled trial carried out at the Clinical Research 
Facility at King’s College Hospital. King’s Clinical Trial Unit randomised participants 
(stratified by gender) to receive a PIL for “a well-known tablet available without 
prescription” that used standard side effect risk information (e.g. ‘Common, 1 in 10 people 
will be affected’) or positively framed wording (e.g. ‘Uncommon, 90% of people will not be 
affected’). After reading their PIL, participants took the tablet (a placebo) and completed 
symptom reports one hour later. The main outcomes included the number of participants who 
attributed symptoms to the tablet, and the number and severity of attributed symptoms. 
Results: 101 participants were assigned the standard PIL and 102 the positive framed PIL. 
Significantly more standard PIL participants attributed symptoms to the tablet (n=55, 54.5%) 
compared to positively framed PIL participants (n=40, 39.2%), OR=0.66, 95% CI[0.46 to 
0.93]. Positive framing did not significantly reduce the total number (p=.148) or severity 
(p=.149) of symptoms attributed to the tablet. 
Conclusion: Positive framing reduced the likelihood of participants attributing nocebo-
induced side effects to the tablet. Work is needed to assess the effectiveness in a patient 
population. 
Trial registration: ISRCTN47470030 
Key words: positive framing, side effects, risk communication, nocebo, placebo 
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Side effects are commonly reported to medications, however many are non-specific 
and not related to the physiological action of the medication (1,2). These non-specific side 
effects may arise through a nocebo effect (3), defined as the experience of unpleasant 
symptoms in response to an inert exposure (4). It is important to try and reduce patients’ 
experience of side effects as they can result in both physical and psychological strain on 
patients. Patients may choose to not take their medication as directed, affecting their health 
(5) and causing financial consequences for the health services (6).  
Nocebo effects are commonly reported in clinical trials, where up to 25% of 
participants receiving an inert, control tablet report side effects (3). They are also common 
outside of the laboratory. For example, although high rates of side effects have been 
attributed to statins among primary care patients (7), clinical trials have found side effect 
rates to be roughly similar in patients allocated statins and those allocated a sham tablet (8,9). 
A recent trial has also shown that the rates of side effects reported to statins are much higher 
when patients know they are receiving statins, rather than when they are blind to their 
treatment allocation (10). ‘Statin intolerance’ may therefore be mediated by a nocebo effect, 
exacerbated by negative expectations generated through patient information leaflets and also 
adverse media coverage (11).  Similar effects have also been proposed for other surprisingly 
high rates of side effect reporting to medications (12-14). 
A recent systematic review by our team of the factors that contribute to nocebo effects 
supported the importance of negative expectations as an underlying mechanism (15). Patients 
who expect symptoms are particularly at risk of reporting them. Although expectations are 
affected by multiple factors, one source that is readily amenable to change are the patient 
information leaflets (PILs) that accompany every medication given out by pharmacists and 
which are read by at least 70% of patients when prescribed new medication (16).  Side effect 
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information in  PILs has long been a source of concern for some researchers who find it 
excessive, inconsistent, and often poorly presented (17). 
Evidence suggests that what symptoms are mentioned in a PIL can affect side effect 
rates (18). More subtly, the way side effect risks are framed may also have an impact. 
Positively framing the risk in terms of the number of people who will not be affected has 
been shown to result in lower expectations of side effects than negatively framing risk in 
terms of the number who will be affected (19). O’Connor et al. (20) reframed the information 
given to participants about side effect risk following an influenza vaccination and found a 
significant decrease in side effects when using positive framing. O’Connor et al’s (20) work 
has never been replicated, however the Medicine and Healthcare products Regulatory Agency 
(MHRA) recommends that framing should not be used in PILs, as patients may perceive it as 
“a marketing ploy”(21). We are unaware of any evidence which supports that assertion.  
We tested whether positively framing side effect risk in a PIL reduces nocebo induced 
side effects and whether it affects satisfaction with or perceived credibility of the PIL. Our 
hypotheses were as follows: 
1. There will be a significant difference in the number of people who attribute 
symptoms to the tablet between the two conditions 
2. There will be a significant difference in the number of symptoms attributed to the 
tablet between the two conditions 
3. There will be a significant difference in the severity of symptoms attributed to the 
tablet between the two conditions 
4. There will be a significant difference in participant-rated satisfaction with the 
information between the two conditions 
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5. There will be a significant difference in participant-rated credibility of the 
information between the two conditions 
Methods 
Design 
A single centre double blind randomised controlled trial, with a between participants 
design was conducted at the Wellcome Trust King's Clinical Research Facility in the UK. 
This study was approved by the Psychiatry, Nursing and Midwifery Research Ethics 
Subcommittee at King’s College London (Reference number: PNM 14/15-62).  
Participants 
Participants who were healthy, aged 18 or over, and fluent in English were invited to 
take part. Participants with chronic or acute illnesses which were currently symptomatic or 
those who were pregnant or breast feeding were excluded to prevent any interference with 
symptom reporting. Participants were asked to list any allergies to medicines and/or the 
inactive ingredients often found in them. Examples of the potential inactive ingredients were 
given and these covered all the ingredients in the tablet. Participants who listed allergies to 
any of the substances in our tablet were also excluded. Participants who had taken any pain 
killers within 4 hours before taking part, or who had been drinking alcohol on the day of 
participation were rescheduled. 
Procedure 
Participants were recruited through adverts on university circular emails and posts on 
GumTree. These adverts presented an outline of the study, inclusion criteria and an email 
address to contact us for further information. Interested participants were emailed an 
information sheet and screening questionnaire. The information sheet explained that the study 
aim was to “assess the severity of short-term side effects to a well-known tablet.” It explained 
that we could not tell participants what the tablet is or what it is used for as we “do not want 
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to bias your views about it”, and that the tablet would be referred to in written materials as 
“XXXXXXX”. The information sheet explained that the tablet has been shown to have 
beneficial effects for people and that no prescription is needed to take it. It stated that the 
tablet can cause short term side effects, and that we wanted to assess how severe these side 
effects are. The information sheet also explained that as part of the study we would 
randomise participants to receive one of two PILs that have been developed for this tablet to 
see if they influence what people think about it. Participants were told that the only difference 
between the two PILs was small changes to the wording, but that we could not tell them what 
would be changed. 
Eligible participants arranged a time with the researcher to participate. After booking 
in at the reception of the clinical research facility, they were led to a fully equipped testing 
room where a researcher double-checked the participants’ screening questionnaire. 
Participants were asked to give written consent. Given the nature of the research, consent was 
not fully informed, although participants were aware that information was being withheld 
from them. After providing consent, participants answered questions about demographics, 
recent symptoms, and anxiety. Participants were randomised to receive one of two leaflets 
about the tablet which they read immediately. The leaflets were sealed in an opaque 
envelope. Participants were given as long as they needed to read the leaflet once before 
putting it back in the envelope. They then answered questions about the credibility of the 
information in the leaflets and their anxiety. Once these questions were completed 
participants took the tablet with water. Over the next hour, they completed a variety of 
vigilance and cognitive tasks, chosen to enhance the appearance that this was a formal 
clinical trial for a drug. In reality, data from these 'filler' tasks were discarded. Participants 
then completed questions about their symptom experience, their anxiety, and what they 
thought the tablet was. All participants received £40 for taking part via shopping vouchers or 
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bank transfer. After all participants had been tested, we contacted participants to explain the 
real nature of the study and to provide an opportunity to withdraw their data if they wished: 
none did. A summary of the procedure can be been seen in Figure 1. The inert tablet was 
manufactured by Guy’s and St Thomas Pharmacy and was stored and dispensed at the 
Pharmacy Department at Maudsley Hospital. 
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Figure 1. Study procedure 
Measures 
At baseline we included demographic questions relating to: age, gender, ethnicity, 
highest level of education, and employment status. Symptoms in the past 24 hours were 
measured using the generic assessment of side effects (GASE) scale (22). The GASE is an 
instrument used to assess side effects in clinical trials and supports the early detection of 
Randomised 
Complete questions about: 
 Demographics 
 Symptoms in past 24 hours 
 State anxiety  
Read standard worded PIL Read positive framed PIL 
Complete questions about: 
 State anxiety 
 Satisfaction with information in 
the PIL 
 Credibility of the PIL  
Take tablet and complete filler tasks 
One hour later, complete questions 
about: 
 Symptom reports 
 Guess at tablet identity 
End of study and monetary reward 
Full debrief at end of all data collection 
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drug-induced adverse events. We modified the scale so that 23 symptoms were selected 
according to those commonly reported during a nocebo response and those listed on the 
GASE that could be detected within an hour of taking the tablet, and were not too serious 
(e.g. headache, dizziness, itchy skin). Fourteen of these symptoms were mentioned on the 
PILs (headache, nausea, cough, dizziness, pain in limb, runny nose, sore throat, stomach 
ache, tiredness, bloating, itchy skin, confusion, agitation, anxiety) and nine were not (chest 
pain, hot flushes, depressed mood, dry mouth, abnormal sweating, breathing problems, 
tremor, palpitation, irritability). Participants rated each symptom on a four point scale ranging 
from “not present” to “severe”. State anxiety was measured using the State Anxiety 
Inventory- short version (23). This includes six items which participants rated on a four point 
scale ranging from “not at all” to “very much”.  Internal consistency of the scale is high with 
a Cronbach’s alpha of 0.82.  
After reading the PIL, satisfaction was measured using seven statements about the 
clarity of the information, the type of information provided and overall satisfaction, which 
participants rated on a five point scale ranging from “strongly disagree” to “strongly agree”, 
and we included a measure of their state anxiety again. To assess the credibility of the PIL we 
used the Myers credibility index (18). Participants rated the information in the PIL on 5 
continuums: trust, accuracy, fairness, bias and disclosure, using a 5 point scale from 1-5. 
Participants’ state anxiety was also measured again after they read the PIL. 
After taking the tablet, we measured participants’ symptom reports using a different 
modification of the GASE, with participants asked to rate each symptom on a four point scale 
ranging from “not present” to “severe”, and asked if any symptom they experienced was 
related to taking the tablet (“yes” or “no”). Finally, participants were asked to give their best 
guess at what the tablet was and to rate how confident they were about this on a scale from 1-
5. 
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Intervention 
The intervention was based on positively framing side effect risk as a way to reduce 
participant’s expectations of side effects, making them less likely to be reported. The 
intervention was delivered through the means of a PIL printed on an A4 sheet of paper given 
to participants by the researcher in a sealed envelope. Participants could receive a standard 
worded PIL akin to those used in current practice, or the intervention PIL. The leaflets were 
designed to be accurate for an inert tablet, providing information on what might be expected 
solely as a result of placebo or nocebo effects. As participants were not told what the tablet 
was, certain sections of the PIL were redacted, with text replaced by a single, large “X”; these 
included the sections: ‘What XXXXXXX is and what it is used for,’ ‘other medicines and 
XXXXXXX,’ ‘recommended doses,’ and ‘what XXXXXXX contains.’ The only difference 
between the two leaflets was the ‘possible side effects’ section. The standard worded PIL 
followed current guidelines for describing side effect risk, e.g. ‘Common side effects (1 in 10 
people will be affected).’ The intervention PIL applied positive framing to the risks, by 
rewording the verbal descriptor, presenting the number of people who would not be affected 
and using percentages which have previously been shown to elevate perceptions of likelihood 
compared to natural frequencies (24). For copies of the leaflets see the electronic 
supplemental material. Pilot testing in a randomised controlled cross-over trial (n=30) 
provided preliminary data that the intervention was effective in changing expectations. 
Randomisation and masking 
Randomisation was carried out by the King’s Clinical Trial Unit (KCTU) using 
randomly varying block sizes, stratified by gender. Participants’ details were entered onto an 
online randomisation system provided by KCTU after they gave consent and an email was 
immediately sent back to the researcher providing a unique envelope number to give to the 
participant. The envelope contained either the standard worded or positively framed PIL. The 
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envelopes were opaque and were pre-packed and sealed in advance by a separate member of 
the team. The researcher was blind to the contents of the envelope. Participants were not told 
the difference between the two leaflets. 
Outcomes 
Our primary outcomes were the number of participants who reported one or more 
symptoms which they attributed to the tablet; the number of symptoms attributed to the 
tablet; and the severity of symptoms attributed to the tablet. 
In a change to our registered protocol, we decided to include satisfaction and 
credibility scores for the two leaflets as secondary outcomes. 
Statistical analysis 
The sample size calculation was based on the assumption that 25% of participants in 
the control condition would develop symptoms (3), and that we were interested in reducing 
this to 10% or lower. To detect this effect as significant at p < .05 with 80% power, using a z-
test for independent proportions, 100 participants were required in each group  
Following consultation with a biostatistician, in a change to our registered protocol 
we used a hurdle model to assess the effect of the intervention on number of participants 
attributing symptoms to the tablet and the number of symptoms attributed to the tablet. This 
consisted of a joint logistic and truncated negative binomial regression. This is a more 
powerful analysis to use for count data when there is an excess number of zeros than would 
be expected by a negative binomial regression. The logistic regression identified the effect of 
leaflet condition on the odds of participants experiencing symptoms as opposed to not 
experiencing symptoms, whilst the truncated negative binomial regression identified the 
effect of leaflet condition on the rate of symptoms attributed to the tablet.  Due to the effect 
that baseline symptoms could have on symptom reporting at follow-up due to misattribution 
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(25,26), we controlled for baseline symptoms in these analyses to give a more accurate result 
for the effect of leaflet condition on reported symptoms. As symptom severity was based on 
scale data, and had a non-normal distribution the effect of the intervention on the severity of 
symptoms that were attributed to the tablet were analysed using Mann-Whitney U tests. 
These analyses were conducted separately for symptoms which were mentioned in the PIL 
and for symptoms not mentioned in the PIL. For completeness we also included an analysis 
of all attributed symptoms, which included both symptoms that were mentioned in the PIL 
and those that were not mentioned in the PIL. 
For the secondary outcomes due to non-normal distributions the difference in 
satisfaction and credibility scores between the PILs was examined using Mann-Whitney U 
tests.  
Due to the influence that baseline anxiety has had on previous experimental studies in 
nocebo research e.g. (27), we carried out a post-hoc analysis using logistic regression, 
controlling for the number of baseline symptoms to assess the interaction between the leaflets 
participants were randomised to receive and baseline anxiety to see if this influenced the odds 
of participants attributing any symptom to the tablet.  
Because of a computer failure, which resulted in data for one participant being 
irretrievably lost, and because we excluded data from the first two participants whom we 
used as pilot runs for the study, our clinical trials unit advised us to recruit an additional six 
participants to ensure the eventual sample size would exceed 100 in each arm. Data for 203 
participants were therefore included in the analyses. All analyses were carried out using SPSS 
version 24.0, apart from the hurdle model which was carried out using Stata version 15. 
Trial registration: ISRCTN47470030 
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Results  
Participants were recruited between Dec 1, 2015 to Dec 5, 2016.The final sample 
contained 203 participants, 101 assigned to the standard worded PIL, and 102 assigned to the 
positively framed PIL (see Figure 2 for participant flow). The mean age of the sample was 
27.15 years. Participants consisted of 65 men and 138 women with the majority being of 
white ethnicity (59.6%). For full baseline characteristics see Table 1. 
Table 1. Baseline characteristics of the sample 
Note: Data are n (%) or mean (SD), PIL = patient information leaflet 
  
Variable 
Standard worded 
PIL (n = 101) 
Positively framed 
PIL (n = 102) 
Total sample 
(N = 203) 
Age 27.28 (8.69) 27.03 (8.61) 27.15 (8.63) 
Gender     
Male 32 (31.7%) 33 (32.4%) 55 (32.0%) 
Female 69 (68.3%) 69 (67.6%) 138 (68.0%) 
Ethnicity    
White 65 (64.4%) 56 (54.9%) 121 (59.6%) 
Other 36 (35.6%) 46 (45.1%) 82 (40.4%) 
Education     
Secondary school 37 (36.6%) 34 (33.3%) 71 (35.0%) 
Higher education 64 (63.4%) 68 (66.7%) 132 (65.0%) 
Employment     
Working 45 (44.6%) 33 (32.4%) 78 (38.4%) 
Not working 56 (55.4%) 69 (67.6%) 125 (61.6%) 
Number of baseline symptoms 2.38 (2.51) 2.81 (2.87) 2.60 (2.60) 
Severity of baseline symptoms 2.65 (2.94) 3.24 (3.59) 2.95 (3.29) 
Baseline anxiety 9.51 (2.58) 9.69 (2.84) 9.60 (2.71) 
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Figure 2.  Trial profile 
Note: Due to the loss of three participants from the sample, our clinical trials unit advised we 
recruited an extra six participants to ensure 100 in each arm as we did not know which 
leaflets the three participants had been assigned 
 
 
 
  
206 randomised 
259 booked in 
317 eligible  
465 interested in the 
study 
-141 did not complete the screening 
questionnaire 
-3 found out from the ISRCTN website 
and potentially knew tablet was a sham 
-1 realised they could not take part as 
they were pregnant  
-3 had a medical condition currently 
causing symptoms and were not eligible 
 
-58 did not book a time to participate 
 
320 completed 
screening  
-38 cancelled and did not reschedule 
-13 did not attend 
-2 taking part in another medical based 
study at the same time so we cancelled 
their booking  
 
-1 ‘pilot run’ excluded 
from final sample 
 
101 included in 
analysis 
102 included in 
analysis 
103 assigned 
positively 
framed leaflet 
103 assigned 
standard 
worded leaflet 
-1 ‘pilot run’ 
excluded from 
final sample 
-1 lost due to 
IT outage  
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Primary outcomes: symptom attribution 
Table 2 shows the results from the primary outcome of the number of people who 
attributed symptoms to the tablet. Fifty (54.5%) participants who received the standard 
worded PIL experienced symptoms which they attributed to the tablet, compared with 40 
(39.2%) participants who received the positively framed PIL. In other words participants who 
received the positively framed PIL were 34% (OR = 0.66) less likely to attribute symptoms to 
the tablet than participants who received the standard worded PIL, whilst adjusting for 
number of baseline symptoms. Similarly, participants who received the positively framed PIL 
were 34% (OR = 0.66) less likely to attribute symptoms mentioned in the PIL to the tablet 
than participants who received the standard worded PIL. There was no difference in the odds 
of attributing symptoms not mentioned in the PIL to the tablet. There was no significant 
difference between the leaflets for the number (all p values > .067) and severity (all p values 
> .149) of symptoms reported that were attributed to the tablet, see Table 2. 
Secondary outcomes: satisfaction and credibility scores 
There was no significant difference between the leaflets in terms of satisfaction with 
or credibility of the PILs (see Table 3). Both leaflets scored well for both outcomes. In 
addition there was no difference in anxiety scores after reading either leaflet. 
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Table 2. The difference in symptom reporting between the two leaflets 
Outcome 
Standard 
worded PIL 
(n = 101) 
Positively 
framed PIL 
(n = 102) 
Test* 
Effect size 
(95% CI) 
Symptoms mentioned in PIL      
Experienced 47 (46.5%) 33 (32.4%) z = -2.25 
p = .024 
OR = 0.66 
(0.46-0.95) Did not experience 54 (53.5%) 69 (67.6%) 
Number of symptoms 0.72 (0.92) 0.69 (1.06) 
z = 1.83         
p = .067 
RR = 1.22 
(0.99-1.50) 
Severity of symptoms 0.78 (1.05) 0.78 (1.43) 
U = 4645.0 
p = .168 
r = - 0.10 
Symptoms not mentioned in PIL      
Experienced 24 (23.8%) 22 (21.6%) z = -0.52   
p = .606 
OR = 0.90 
(0.61-1.33) Did not experience 77 (76.2%) 80 (78.4%) 
Number of symptoms 0.32 (0.65) 0.33 (0.71) 
z = 0.73      
p = .467 
RR = 1.09 
(0.86-1.34) 
Severity of symptoms 0.38 (0.83) 0.40 (0.95) 
U = 5063.0 
p = .774 
r = - 0.02 
Any symptoms     
Experienced 55 (54.5%) 40 (39.2%) z = -2.35 
p = .019 
OR = 0.66 
(0.46-0.93) Did not experience 46 (45.5%) 62 (60.8%) 
Number of symptoms 1.04 (1.22) 1.01 (1.73) 
z = 1.45       
p = .148 
RR = 1.19 
(0.94-1.50) 
Severity of symptoms 1.16 (1.46) 1.21 (2.14) 
U = 4596.5 
p = .149 
r = - 0.10 
Note: Data are n (%) or mean (SD), OR = Odds ratio, RR = rate ratio, PIL = patient 
information leaflet, * = all adjusted for number of baseline symptoms apart from symptom 
severity tests, r = pearson’s correlation which can be calculated from Mann-Whitney U 
output. 95% CI for r is not able to be calculated from Mann-Whitney U output. 
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Table 3. The difference in satisfaction and credibility median scores between the two leaflets 
Outcomes 
Standard  
worded PIL 
(n = 101) 
Positively 
framed PIL 
(n = 102) 
Test 
Effect 
size 
Satisfaction     
Leaflet was clear 4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 5024.5 
p = .730 
r = - 0.02 
Leaflet was easy to 
understand 
4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4971.0 
p = .617 
r = - 0.04 
Leaflet contained words I 
did not understand 
1.0 (1.0-2.0) 1.0 (1.0-2.0) 
U = 5021.0 
p = .718 
r = - 0.03 
Leaflet was similar to 
other leaflets 
4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4934.5 
p = .557 
r = - 0.04 
There was enough 
information to make an 
informed choice 
3.0 (3.0-5.0) 4.0 (4.0-4.0) 
U = 5118.5 
p = .932 
r = - 0.01 
There was sufficient 
information about the 
risks and benefits 
4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4980.5 
p = .642 
r = - 0.03 
Overall I am satisfied with 
the leaflet 
4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4870.0 
p = .451 
r = - 0.05 
  Anxiety after reading the      
leaflet 
9.0 (8.0-11.0) 9.0 (7.75-11.25) 
U = 5037.0 
p = .783 
r = - 0.02 
Credibility 
    
Trustworthy 4.0 (4.0-5.0) 4.0 (4.0-4.0) 
U = 4691.0 
p = .202 
r = - 0.09 
Accurate 4.0 (4.0-4.0) 4.0 (4.0-4.0) 
U = 5003.0 
p = .690 
r = - 0.02 
Fair 4.0 (4.0-4.0) 4.0 (4.0-4.0) 
U = 5126.0 
p = .946 
r = - 0.01 
Tells the whole story 3.0 (3.0-4.0) 3.0 (3.0-4.0) 
U = 5096.5 
p = .892 
r = - 0.01 
Unbiased 4.0 (3.0-4.0) 4.0 (3.0-4.0) 
U = 4639.5 
p = .191 
r = - 0.09 
Note: Data are median (IQR), PIL = patient information leaflet, pearson’s correlation r has been 
calculated as an effect size from Mann-Whitney U output. 95% CI for r is unable to be calculated 
from Mann-Whitney U output. 
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Post-hoc analysis 
For the post-hoc analysis there was no significant interaction between the leaflet type 
and participants’ baseline anxiety scores, controlling for number of baseline symptoms, OR = 
1.056, p = .054, 95% CI [0.999 to 1.116]. 
Guess at tablet identity 
The majority (49.8%) of participants thought the tablet was an over the counter 
analgesic such as paracetamol, ibuprofen, or aspirin. Nearly a third of participants (31.5%) 
did not know what the tablet was. Participants’ confidence in their guesses as to tablet 
identify was low, with a mean score of 1.88 out of 5 for participants who did not give an 
answer of ‘Don’t know’. Only 9 participants guessed that the tablet was a sham, with the 
mean confidence of participants who guessed this being low (2.22 out of 5). Five of these 
received the standard worded PIL and four received the positively framed PIL.  
Sensitivity analyses 
Excluding the nine participants who guessed it was a placebo from the analyses did 
not change the outcome of any of the results, apart from the post-hoc analysis. In this instance 
for each one point increase in baseline anxiety score participants were 1.06 times as likely to 
experience symptoms if they received the standard worded PIL compared to the positively 
framed PIL. See supplementary material for full results of sensitivity analyses.  
Discussion 
The results from this study show that positive framing of side effect information 
reduces the likelihood of participants experiencing symptoms which they attribute to a 
recently taken tablet. This reduction is clearly linked to the phrasing used in the leaflet – it 
applies only to those symptoms described in the leaflet and not to others. This finding 
supports  previous work showing the effectiveness of positive framing of side effect 
information in reducing side effect reporting following influenza vaccination (20). Despite 
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previous claims that positive framing might be seen as a marketing ploy by patients (21), 
there was no difference in participant satisfaction for the two leaflets or their perceived 
credibility.  
This was a well-controlled and adequately powered study, with both participants and 
researcher blind to the experimental condition.  Although nine participants guessed the tablet 
was a sham, the most common reason given for this was because they did not experience any 
effects from the tablet. Only two participants who guessed it was an inert tablet suggested this 
because they thought we were testing how side effect information affected symptom 
development, although both had low confidence in their guess.  This shows the strength of 
the model used here for work on the nocebo effect and supports the credibility of the study. 
Although ethical issues are raised through the use of deception to elicit symptoms in 
participants, the information we gave to participants was accurate, in that it correctly 
conveyed what we know about placebo and nocebo effects. In addition we made participants 
aware that information was being withheld from them, thereby using an ‘authorised 
deception’ approach to consent. Our method was well received by participants. At the end of 
data collection participants were emailed a debrief explaining the study aims. Sixteen 
participants replied, expressing pleasant surprise and interest. No-one responded negatively. 
One limitation inherent in our design was that participants were more focussed on 
monitoring themselves for symptoms than they might have been in daily life after taking a 
tablet. Although we attempted to reduce this effect by occupying participants with cognitive 
tasks after taking the tablet, this effect is likely to have raised levels of symptom reporting in 
both experimental conditions. Other limitations include the fact that our sample was not 
representative of the general public, in particular being well-educated, with 65% having a 
higher education qualification, and young, with a mean age of 27. Also, as participants 
volunteered knowing that we were investigating side effects to a tablet, it is possible that 
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those who volunteered were people who were generally trusting of medications or medical 
science. This could explain why no interaction was found between baseline anxiety and 
leaflet type, as participants’ anxiety was already quite low. Given that these factors may 
reduce the likelihood of nocebo effects occurring, the number of participants who attributed 
symptoms to our tablet, and the number and severity of these attributed symptoms is likely to 
be an underestimate compared to the general public. 
Another limitation concerns the fact that we altered two parts of the side effect 
information in the intervention PIL – the numeric and verbal risk information. This means we 
cannot tell if only one part is causing the effect or if there is a cumulative effect of the 
numeric and verbal information. Further study is needed to explore this. In addition our 
follow-up period of one hour may have been a limitation. It is possible that a longer follow-
up may have altered the results in different ways. For example participants may have been 
more likely to experience unrelated physical symptoms and misattribute them to the tablet, or 
it may be that the framing manipulation would have worn off after a longer period of time. 
Our findings suggest that framing the risk of side effects in PILs positively in terms of 
those who will remain side effect free has the potential to reduce the risk of nocebo induced 
side effects that patients experience to their medications. There would be no financial cost to 
implementing the intervention, which could be easily introduced throughout the healthcare 
system. Importantly it does not infringe participants’ ability to give fully informed consent, 
something which has been a concern about previous proposed interventions (28). Nonetheless 
it is important for future research to test the effectiveness of positive framing in a more 
realistic situation, for example with patients with clinical conditions prescribed real 
medication. Two issues in particular require further attention. First, does positive framing 
reduce the likelihood of patients reporting severe side effects to their physician? This would 
be undesirable if so. Second, is the intervention only effective in the short term? It is possible, 
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for example, that over a longer period of time patients will forget the information in the 
leaflet, reducing the impact of the positive framing. 
Nocebo induced side effects attributed to medications result in a significant cost to the 
NHS and to patients’ quality of life. Positive framing of side effect information in PILs 
appears to be a cheap, effective intervention to reduce the risk of this occurring, and does not 
affect patients’ ability to give fully informed consent. Future work is needed to assess the 
effectiveness in a more realistic setting. 
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Supplementary material: 
Standard worded leaflet 
Package Leaflet: Information for 
the user 
 
XXXXXXX hard tablets 
Oseltamivir 
 
Read this leaflet carefully because it 
contains important information for you. 
 Keep this leaflet. You may need to read it 
again. 
 If you have further questions, ask your 
doctor or pharmacist. 
 If you get any side effects, talk to your 
doctor or pharmacist. This includes any 
possible side effects not listed in this 
leaflet. See section 4. 
 
What is in this leaflet 
1. What XXXXXXX is and what it is used 
for 
2. What you need to know before you take   
XXXXXXX 
3. How to take XXXXXXX 
4. Possible side effects 
5. How to store XXXXXXX 
6. Contents of the pack and other 
information 
 
1. What XXXXXXX is and what it 
is used for 
 
XXXXXXX is generally used for adults, 
adolescents, infants and children 1 year old 
and older. 
 XXXXXXX is prescribed for treating flu 
(influenza). It can be used when you have 
flu symptoms, and the flu virus is known 
to be going round in your community. 
 XXXXXXX can also be prescribed for 
preventing flu, on a case-by-case basis – 
for instance, if you have been in contact 
with someone who has flu. 
 XXXXXXX may be prescribed as 
preventive treatment in exceptional 
circumstances – for example, if there is a 
global epidemic of flu (a flu pandemic) 
and the seasonal flu vaccine may not 
provide sufficient protection. 
 
 
 
 
2. What you need to know before 
you take XXXXXXX 
 
Do not take XXXXXXX: 
 if you are allergic to any of the 
ingredients of XXXXXXX listed in 
section 6. 
 
Warnings and precautions: 
Before you take XXXXXXX, talk to your 
doctor 
 if you are allergic to other over-the-
counter tablets 
 If you have diabetes 
 if you have a severe medical condition, 
which may require immediate 
hospitalisation 
 
Other tablets and XXXXXXX 
 
 
 
 
Pregnancy and breast-feeding 
XXXXXXX has no known effect on pregnant 
women, women trying to conceive or on 
breast-fed infants. 
 
Driving and using machines 
XXXXXXX has been known to have an effect 
on your ability to drive or use machines due to 
the occurrence of possible side effects. If you 
are affected do not drive or use machines until 
the side effects wear off. 
 
3. How to take XXXXXXX 
 
Take this tablet exactly as your doctor or 
pharmacist has told you. Check with your 
doctor or pharmacist if you are not sure. 
 
The recommended doses 
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Method of administration 
Swallow the tablet with water. The tablet can 
be divided into two equal halves. 
Do not chew the tablet. 
XXXXXXX can be taken with or without 
food. But it is recommended to be taken 
without food to achieve the greatest effect. 
 
If you take more XXXXXXX than you 
should 
Stop taking XXXXXXX. 
In most cases of overdose, people have 
reported an increased number and severity of 
side effects. When side effects were reported, 
they were similar to those from normal doses, 
as listed in section 4. 
 
If you forget to take XXXXXXX 
Take the next tablet as soon as you remember. 
 
4. Possible side effects 
 
Like all tablets, this tablet can cause side 
effects, although not everybody gets them.  
These side effects mostly occur within one 
hour after taking the first tablet and will 
usually stop as you continue to take them. 
 
Very common side effects 
(More than 1 in 10 people will be affected) 
 Headache 
 Nausea 
 
Common side effects 
(1 in 10 people will be affected) 
 Cough 
 Dizziness 
 Pain in limb 
 Runny nose 
 Sore throat 
 Stomach ache 
 Tiredness 
 Bloating 
 
Uncommon side effects 
(1 in 100 people will be affected) 
 Itchy skin 
 
Rare side effects 
(1 in 1,000 people will be affected) 
 Confusion 
 Agitation 
 Anxiety 
 
Reporting of side effects 
If you get any side effects, talk to your doctor. 
This includes any possible side effects not 
listed in this leaflet.  
 
5. How to store XXXXXXX 
 
Keep out of the sight and reach of children. 
Do not use this tablet after the expiry date 
which is stated on the carton and blister after 
EXP. The expiry date refers to the last day of 
that month. 
Do not store above 25 °C. 
Do not throw away any tablets via wastewater 
or household waste. Ask your pharmacist how 
to throw away tablets you no longer use. These 
measures will help protect the environment. 
 
6. Contents of the pack and other 
information 
 
What XXXXXXX contains 
 Each hard capsule contains oseltamivir 
equivalent to 75 mg of oseltamivir 
phosphate 
 The other ingredients are: 
o Bindng agents: pregelatinised 
starch, talc, povidone, 
croscarmellose sodium and 
sodium stearyl fumarate 
 
What XXXXXXX looks like  
The tablets have a round white opaque body 
with a breakline. 
 
This leaflet was last revised in 08/2015 
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Supplementary material: 
Positively framed leaflet 
Package Leaflet: Information for 
the user 
 
XXXXXXX hard tablets 
Oseltamivir 
 
Read this leaflet carefully because it 
contains important information for you. 
 Keep this leaflet. You may need to read it 
again. 
 If you have further questions, ask your 
doctor or pharmacist. 
 If you get any side effects, talk to your 
doctor or pharmacist. This includes any 
possible side effects not listed in this 
leaflet. See section 4. 
 
What is in this leaflet 
7. What XXXXXXX is and what it is used 
for 
8. What you need to know before you take   
XXXXXXX 
9. How to take XXXXXXX 
10. Possible side effects 
11. How to store XXXXXXX 
12. Contents of the pack and other 
information 
 
1. What XXXXXXX is and what it 
is used for 
 
XXXXXXX is generally used for adults, 
adolescents, infants and children 1 year old 
and older. 
 XXXXXXX is prescribed for treating flu 
(influenza). It can be used when you have 
flu symptoms, and the flu virus is known 
to be going round in your community. 
 XXXXXXX can also be prescribed for 
preventing flu, on a case-by-case basis – 
for instance, if you have been in contact 
with someone who has flu. 
 XXXXXXX may be prescribed as 
preventive treatment in exceptional 
circumstances – for example, if there is a 
global epidemic of flu (a flu pandemic) 
and the seasonal flu vaccine may not 
provide sufficient protection. 
 
 
 
 
2. What you need to know before 
you take XXXXXXX 
 
Do not take XXXXXXX: 
 if you are allergic to any of the 
ingredients of XXXXXXX listed in 
section 6. 
 
Warnings and precautions: 
Before you take XXXXXXX, talk to your 
doctor 
 if you are allergic to other over-the-
counter tablets 
 If you have diabetes 
 if you have a severe medical condition, 
which may require immediate 
hospitalisation 
 
Other tablets and XXXXXXX 
 
 
 
 
Pregnancy and breast-feeding 
XXXXXXX has no known effect on pregnant 
women, women trying to conceive or on 
breast-fed infants. 
 
Driving and using machines 
XXXXXXX has been known to have an effect 
on your ability to drive or use machines due to 
the occurrence of possible side effects. If you 
are affected do not drive or use machines until 
the side effects wear off. 
 
3. How to take XXXXXXX 
 
Take this tablet exactly as your doctor or 
pharmacist has told you. Check with your 
doctor or pharmacist if you are not sure. 
 
The recommended doses 
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Method of administration 
Swallow the tablet with water. The tablet can 
be divided into two equal halves. 
Do not chew the tablet. 
XXXXXXX can be taken with or without 
food. But it is recommended to be taken 
without food to achieve the greatest effect. 
 
If you take more XXXXXXX than you 
should 
Stop taking XXXXXXX. 
In most cases of overdose, people have 
reported an increased number and severity of 
side effects. When side effects were reported, 
they were similar to those from normal doses, 
as listed in section 4. 
 
If you forget to take XXXXXXX 
Take the next tablet as soon as you remember. 
 
4. Possible side effects 
 
Like all tablets, this tablet can cause side 
effects, although not everybody gets them.  
These side effects mostly occur within one 
hour after taking the first tablet and will 
usually stop as you continue to take them. 
 
Uncommon side effects 
(80% of people will not be affected) 
 Headache 
 Nausea 
 
Very uncommon side effects 
(90% of people will not be affected) 
 Cough 
 Dizziness 
 Pain in limb 
 Runny nose 
 Sore throat 
 Stomach ache 
 Tiredness 
 Bloating 
 
Rare side effects 
(99% of people will not be affected) 
 Itchy skin 
 
Very rare side effects 
(99.9% of people will not be affected) 
 Confusion 
 Agitation 
 Anxiety 
Reporting of side effects 
If you get any side effects, talk to your doctor. 
This includes any possible side effects not 
listed in this leaflet.  
 
5. How to store XXXXXXX 
 
Keep out of the sight and reach of children. 
Do not use this tablet after the expiry date 
which is stated on the carton and blister after 
EXP. The expiry date refers to the last day of 
that month. 
Do not store above 25 °C. 
Do not throw away any tablets via wastewater 
or household waste. Ask your pharmacist how 
to throw away tablets you no longer use. These 
measures will help protect the environment. 
 
6. Contents of the pack and other 
information 
 
What XXXXXXX contains 
 Each hard capsule contains oseltamivir 
equivalent to 75 mg of oseltamivir 
phosphate 
 The other ingredients are: 
o Bindng agents: pregelatinised 
starch, talc, povidone, 
croscarmellose sodium and 
sodium stearyl fumarate 
 
What XXXXXXX looks like  
The tablets have a round white opaque body 
with a breakline. 
 
This leaflet was last revised in 08/2015 
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Supplementary material: Sensitivity analyses - rerunning analyses without the 9 
participants who guessed that the tablet was a placebo 
 
The difference in symptom reporting between the two leaflets 
Outcome 
Standard 
worded PIL 
(n = 96) 
Positively 
framed PIL 
(n = 98) 
Test* 
Effect size 
(95% CI) 
Symptoms mentioned in PIL      
Experienced 46 (47.9%) 33 (33.7%) z = -2.25 
p = .024 
OR = 0.66 
(0.46-0.95) Did not experience 50 (52.1%) 65 (66.3%) 
Number of symptoms 0.75 (0.93) 0.69 (1.20) 
z = 1.69         
p = .091 
RR = 1.20 
(0.97-1.48) 
Severity of symptoms 0.81 (1.06) 0.82 (1.45) 
U = 4247.5 
p = .187 
r = - 0.09 
Symptoms not mentioned in PIL      
Experienced 24 (25.0%) 21 (21.4%) z = -0.82   
p = .411 
OR = 0.85 
(0.57-1.26) Did not experience 72 (75.0%) 77 (78.6%) 
Number of symptoms 0.33 (0.66) 0.35 (0.79) 
z = 0.76      
p = .449 
RR = 1.10 
(0.86-1.39) 
Severity of symptoms 0.40 (0.85) 0.41 (1.06) 
U = 4565.5 
p = .631 
r = - 0.03 
Any symptoms     
Experienced 54 (56.3%) 39 (39.8%) z = -2.54 
p = .011 
OR = 0.63 
(0.43-0.90) Did not experience 42 (43.8%) 59 (60.2%) 
Number of symptoms 1.08 (1.23) 1.04 (1.75) 
z = 1.42       
p = .155 
RR = 1.19 
(0.94-1.51) 
Severity of symptoms 1.21 (1.48) 1.23 (2.17) 
U = 4162.0 
p = .1433 
r = - 0.12 
Note: Data are n (%) or mean (SD), OR = Odds ratio, RR = rate ratio, PIL = patient 
information leaflet, * = all adjusted for number of baseline symptoms apart from symptom 
severity tests, r = pearson’s correlation which can be calculated from Mann-Whitney U 
output. 95% CI for r is not able to be calculated from Mann-Whitney U output. 
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The difference in satisfaction and credibility median scores between the two leaflets 
Outcomes 
Standard  
worded PIL 
(n = 96) 
Positively 
framed PIL 
(n = 98) 
Test Effect size 
Satisfaction     
Leaflet was clear 4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4571.0 
p = .700 
r = - 0.03 
Leaflet was easy to 
understand 
4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4467.5 
p = .485 
r = - 0.05 
Leaflet contained words 
I did not understand 
1.0 (1.0-2.0) 1.0 (1.0-2.0) 
U = 4553.5 
p = .655 
r = - 0.03 
Leaflet was similar to 
other leaflets 
4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4476.0 
p = .509 
r = - 0.05 
There was enough 
information to make an 
informed choice 
4.0 (3.0-5.0) 4.0 (4.0-4.0) 
U = 4568.0 
p = .705 
r = - 0.03 
There was sufficient 
information about the 
risks and benefits 
4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4485.5 
p = .526 
r = - 0.05 
Overall I am satisfied 
with the leaflet 
4.0 (4.0-5.0) 4.0 (4.0-5.0) 
U = 4344.5 
p = .305 
r = - 0.07 
Anxiety after reading the 
leaflet 
9.0 (8.0-11.0) 9.0 (7.0-11.0) 
U = 4555.0 
p = .700 
r = - 0.03 
Credibility     
Trustworthy 4.0 (4.0-5.0) 4.0 (4.0-4.0) 
U = 4250.5 
p = .177 
r = - 0.09 
Accurate 4.0 (4.0-5.0) 4.0 (4.0-4.0) 
U = 4546.0 
p = .646 
r = - 0.03 
Fair 4.0 (4.0-4.0) 4.0 (4.0-4.0) 
U = 4615.0 
p = .797 
r = - 0.02 
Tells the whole story 3.0 (3.0-4.0) 3.0 (3.0-4.0) 
U = 4685.5 
p = .961 
r = - 0.004 
Unbiased 4.0 (3.0-4.0) 4.0 (3.0-4.0) 
U = 4156.0 
p = .133 
r = - 0.12 
Note: Data are median (IQR), PIL = patient information leaflet, pearson’s correlation r has 
been calculated as an effect size from Mann-Whitney U output. 95% CI for r is unable to be 
calculated from Mann-Whitney U output. 
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Post-hoc analysis 
There was a significant interaction between the leaflet type and participants’ baseline anxiety 
scores, controlling for number of baseline symptoms, OR = 1.06, p = .037, 95% CI [1.004 to 
1.124]. For each one point increase in baseline anxiety score participants were 1.06 times as 
likely to experience symptoms if they received the standard worded PIL compared to the 
positively framed PIL. 
 
 
 
 
